S179: RANDOMIZED COMPARISON BETWEEN KRD AND KTD INDUCTION, FOLLOWED BY K MAINTENANCE OR OBSERVATION IN TRANSPLANT NON-ELIGIBLE PATIENTS WITH NDMM (AGMT-MM02 TRIAL)

S179: RANDOMIZED COMPARISON BETWEEN KRD AND KTD INDUCTION, FOLLOWED BY K MAINTENANCE OR OBSERVATION IN TRANSPLANT NON-ELIGIBLE PATIENTS WITH NDMM (AGMT-MM02 TRIAL)

Bibliographic Details
Main Authors:	H. Ludwig, T. Melchardt, S. Sormann, N. Zojer, J. Andel, B. Hartmann, C. Tinchon, E. Gunsilius, K. Podar, A. Egle, W. Willenbacher, E. Wöll, M. Schreder, R. Ruckser, B Bozic, M.-T. Krauth, A. Petzer, C Schmitt, S. Machherndl-Spandl, H. Agis, M. Fillitz, W. Pönisch, S. Knop, B. Paiva, R. Greil
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000843608.22124.95

Similar Items

P943: OUTCOME ANALYSIS BY CYTOGENETIC RISK GROUP AFTER RANDOMIZATION TO KRD OR KTD FOLLOWED BY K MAINTENANCE OR CONTROL IN PATIENTS WITH NTE NDMM (AGMT MM-02)
by: Heinz Ludwig, et al.
Published: (2023-08-01)

Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents—A Prospective Cohort Study of the AGMT Study-Group
by: Michael Leisch, et al.
Published: (2022-05-01)

Reduced alpha diversity of the oral microbiome correlates with short progression‐free survival in patients with relapsed/refractory multiple myeloma treated with ixazomib‐based therapy (AGMT MM 1, phase II trial)
by: Heinz Ludwig, et al.
Published: (2021-02-01)

Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial)
by: Gabriel Rinnerthaler, et al.
Published: (2018-11-01)

Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry
by: Simon Peter Gampenrieder, et al.
Published: (2021-12-01)

Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: results of a phase II trial (AGMT MBC-6)
by: Gabriel Rinnerthaler, et al.
Published: (2021-10-01)

KTD e-library system
by: Azmi, Jannaltul Firdaus
Published: (2006)

KTD e-library system /
by: 357408 Jannaltul Firdaus Azmi
Published: (2006)

Health-Related Quality of Life as Assessed by the EQ-5D-5L Predicts Outcomes of Patients Treated with Azacitidine—A Prospective Cohort Study by the AGMT
by: Lisa Pleyer, et al.
Published: (2023-02-01)

KTD e-library system [compact disc] /
by: 357408 Jannaltul Firdaus Azmi
Published: (2006)

Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL‐8a mabtenance trial
by: Alexander Egle, et al.
Published: (2019-04-01)

MM-KTD: Multiple Model Kalman Temporal Differences for Reinforcement Learning
by: Parvin Malekzadeh, et al.
Published: (2020-01-01)

Phase II single-arm study of a combination of obinutuzumab and venetoclax in early relapsed or refractory diffuse large B-cell lymphoma—final results of the AGMT NHL15B study
by: Ulrich Jaeger, et al.
Published: (2024-03-01)

Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group
by: Lisa Pleyer, et al.
Published: (2017-02-01)

Incorporating hematopoietic stem-cell transplantation after second-line carfilzomib-lenalidomide-dexamethasone (KRd)
by: Ja Min Byun, et al.
Published: (2020-05-01)

Myeloid NGS Analyses of Paired Samples from Bone Marrow and Peripheral Blood Yield Concordant Results: A Prospective Cohort Analysis of the AGMT Study Group
by: Bettina Jansko-Gadermeir, et al.
Published: (2023-04-01)

Attrition Rates in Multiple Myeloma Treatment under Real World Conditions—An Analysis from the Austrian Myeloma Registry (AMR)
by: Magdalena A. Benda, et al.
Published: (2023-02-01)

S174: MYELOID NGS ANALYSES OF PAIRED SAMPLES FROM BONE MARROW AND PERIPHERAL BLOOD YIELD CONCORDANT RESULTS: A PROSPECTIVE COHORT ANALYSIS OF THE AGMT STUDY GROUP
by: Lisa Pleyer, et al.
Published: (2023-08-01)

The Agony of Choice—Where to Place the Wave of BCMA-Targeted Therapies in the Multiple Myeloma Treatment Puzzle in 2022 and Beyond
by: Irene Strassl, et al.
Published: (2021-09-01)

Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
by: Carlyn Rose Tan, et al.
Published: (2023-07-01)

Local and Central Evaluation of HER2 Positivity and Clinical Outcome in Advanced Gastric and Gastroesophageal Cancer—Results from the AGMT GASTRIC-5 Registry
by: Florian Huemer, et al.
Published: (2020-03-01)

PB2023: UPDATE AND FOLLOW-UP OF NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) WITH HIGH-RISK CYTOGENETIC (HRC).
by: M. I. Nuevo López, et al.
Published: (2022-06-01)

P09: ATTRITION RATES IN MULTIPLE MYELOMA UNDER REAL WORLD CONDITIONS – AN ANALYSIS FROM THE AUSTRIAN MYELOMA REGISTRY
by: MA Benda, et al.
Published: (2022-04-01)

BUZZ GROUP DALAM MENINGKATKAN PENGETAHUAN DAN SIKAP REMAJA DALAM PENCEGAHAN KEHAMILAN TIDAK DIINGINKAN (KTD)
by: Sofiana Salim, et al.
Published: (2014-10-01)

BUZZ GROUP DALAM MENINGKATKAN PENGETAHUAN DAN SIKAP REMAJA DALAM PENCEGAHAN KEHAMILAN TIDAK DIINGINKAN (KTD)
by: Sofiana Salim, et al.
Published: (2014-10-01)

ABORSI AKIBAT KEHAMILAN YANG TAK DIINGINKAN (KTD): Kontestasi Antara Pro-Live dan Pro-Choice
by: Mufliha Wijayati
Published: (2017-04-01)

The African Genomic Medicine Training Initiative (AGMT): Showcasing a Community and Framework Driven Genomic Medicine Training for Nurses in Africa
by: Victoria Nembaware, et al.
Published: (2019-12-01)

PERSEPSI REMAJA TENTANG ABORSI KARENA KEHAMILAN TIDAK DIKEHENDAKI (KTD) DI KOTA PONTIANAK PROPINSI KALIMANTAN BARAT
by: , Yenny, et al.
Published: (2013)

AGMT3-D: A software for 3-D landmarks-based geometric morphometric shape analysis of archaeological artifacts.
by: Gadi Herzlinger, et al.
Published: (2018-01-01)

P893: CARFILZOMIB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE (KRD) AS SALVAGE THERAPY FOR MULTIPLE MYELOMA PATIENTS: ITALIAN, MULTICENTER, RETROSPECTIVE EXPERIENCE OUTSIDE OF CLINICAL TRIALS
by: E. A. Martino, et al.
Published: (2022-06-01)

P872: DEL(1P32) REMAINS A POWERFUL PROGNOSTIC FACTOR IN A LARGE COHORT OF NDMM PATIENTS: AN UPDATE
by: A. Schavgoulidze, et al.
Published: (2022-06-01)

PB2016: COMPARISON BETWEEN DRD VS KRD AS SALVAGE THERAPY FOR MULTIPLE MYELOMA PATIENTS IN FIRST RELAPSE: THE REAL LIFE EXPERIENCE OF RETE EMATOLOGICA PUGLIESE (REP)
by: A. Mele, et al.
Published: (2022-06-01)

PB2134: BCMA-TARGETED THERAPIES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION – A SINGLE CENTER EXPERIENCE
by: Irene Strassl, et al.
Published: (2023-08-01)

P937: CARFILZOMIB, LENALIDOMIDE PLUS DEXAMETHASONE (KRD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: UPDATE ANALYSIS OF REAL-LIFE EXPERIENCE OF GEMMAC GROUP.
by: Antonio Garcia-Guiñon, et al.
Published: (2023-08-01)

Sidik Cepat Potensi Karst Rocky Desertification (KRD) Menggunakan Citra Landsat 8 OLI: Studi di Kawasan Karst Gunungsewu Bagian Barat
by: Pendi Tri Sutrisno, et al.
Published: (2020-09-01)

P08 TEMPORAL TRENDS IN PROGNOSIS OF PATIENTS WITH SMOLDERING MULTIPLE MYELOMA (SMM) WHO MEET CRITERIA FOR BIOMARKER-DEFINED EARLY MULTIPLE MYELOMA (SLIM CRAB POSITIVE MM)
by: H. Ludwig, et al.
Published: (2023-05-01)

PRELIMINARY RESULTS OF DARATUMUMAB, CYCLOPHOSPHAMIDE, THALIDOMIDE AND DEXAMETHASONE: A QUADRUPLET INTENSIED TREATMENT FOR NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) TRANSPLANT ELIGIBLE (TE) PATIENTS
by: E.Q. Crusoé, et al.
Published: (2020-11-01)

PENCEGAHAN KEHAMILAN TIDAK DIINGINKAN (KTD) PADA REMAJA PUTRI YANG AKTIF SEKSUAL DI WILAYAH KERJA POSKESDES KEREMBONG, LOMBOK TENGAH
by: Siti Mardiyah WD, et al.
Published: (2019-03-01)

Prognostic Value of Lenalidomide Maintenance Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM); A Single Center Experience-A Retrospective Study
by: Ali Eser, et al.
Published: (2021-04-01)

DARATUMUMAB (DARA), CYCLOPHOSPHAMIDE, THALIDOMIDE AND DEXAMETHASONE: A QUADRUPLET INTENSIFIED TREATMENT FOR TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (TE NDMM) PATIENTS
by: EQ Crusoe, et al.
Published: (2021-10-01)